JP2011516423A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2011516423A5 JP2011516423A5 JP2011502108A JP2011502108A JP2011516423A5 JP 2011516423 A5 JP2011516423 A5 JP 2011516423A5 JP 2011502108 A JP2011502108 A JP 2011502108A JP 2011502108 A JP2011502108 A JP 2011502108A JP 2011516423 A5 JP2011516423 A5 JP 2011516423A5
- Authority
- JP
- Japan
- Prior art keywords
- molecule
- sequence
- virus
- item
- antibody
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 101710154606 Hemagglutinin Proteins 0.000 claims description 36
- 101710093908 Outer capsid protein VP4 Proteins 0.000 claims description 36
- 101710135467 Outer capsid protein sigma-1 Proteins 0.000 claims description 36
- 101710176177 Protein A56 Proteins 0.000 claims description 36
- 239000000185 hemagglutinin Substances 0.000 claims description 32
- 239000000427 antigen Substances 0.000 claims description 27
- 102000036639 antigens Human genes 0.000 claims description 27
- 108091007433 antigens Proteins 0.000 claims description 27
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 27
- 241000712431 Influenza A virus Species 0.000 claims description 25
- 229920001184 polypeptide Polymers 0.000 claims description 22
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 22
- 238000006467 substitution reaction Methods 0.000 claims description 19
- 229960005486 vaccine Drugs 0.000 claims description 14
- 230000003472 neutralizing effect Effects 0.000 claims description 13
- 108010018324 Surrogate Immunoglobulin Light Chains Proteins 0.000 claims description 12
- 102000002663 Surrogate Immunoglobulin Light Chains Human genes 0.000 claims description 12
- 101000854886 Homo sapiens Immunoglobulin iota chain Proteins 0.000 claims description 8
- 102100020744 Immunoglobulin iota chain Human genes 0.000 claims description 8
- 239000012634 fragment Substances 0.000 claims description 8
- 238000000034 method Methods 0.000 claims description 6
- 230000003612 virological effect Effects 0.000 claims description 6
- 241000700605 Viruses Species 0.000 claims description 5
- 210000004602 germ cell Anatomy 0.000 claims description 4
- 150000001413 amino acids Chemical class 0.000 claims description 3
- 230000035931 haemagglutination Effects 0.000 claims description 3
- 239000000203 mixture Substances 0.000 claims description 3
- -1 Kabat amino acid Chemical class 0.000 claims description 2
- 210000004027 cell Anatomy 0.000 claims description 2
- 125000003275 alpha amino acid group Chemical group 0.000 description 18
- 108091035707 Consensus sequence Proteins 0.000 description 8
- 241000713772 Human immunodeficiency virus 1 Species 0.000 description 2
- 241000713340 Human immunodeficiency virus 2 Species 0.000 description 2
- 241000712461 unidentified influenza virus Species 0.000 description 2
- 241000701022 Cytomegalovirus Species 0.000 description 1
- 241000725619 Dengue virus Species 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 208000031886 HIV Infections Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 241000598436 Human T-cell lymphotropic virus Species 0.000 description 1
- 206010020460 Human T-cell lymphotropic virus type I infection Diseases 0.000 description 1
- 241000714260 Human T-lymphotropic virus 1 Species 0.000 description 1
- 241000714259 Human T-lymphotropic virus 2 Species 0.000 description 1
- 241000701085 Human alphaherpesvirus 3 Species 0.000 description 1
- 241000701044 Human gammaherpesvirus 4 Species 0.000 description 1
- 201000005505 Measles Diseases 0.000 description 1
- 208000005647 Mumps Diseases 0.000 description 1
- 241000315672 SARS coronavirus Species 0.000 description 1
- 241000700584 Simplexvirus Species 0.000 description 1
- 241000710886 West Nile virus Species 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 102220352372 c.148T>G Human genes 0.000 description 1
- 206010014599 encephalitis Diseases 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 208000010805 mumps infectious disease Diseases 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 102200006531 rs121913529 Human genes 0.000 description 1
- 102200077933 rs137854432 Human genes 0.000 description 1
- 102200008957 rs387906911 Human genes 0.000 description 1
- 102200133079 rs74315446 Human genes 0.000 description 1
- 201000005404 rubella Diseases 0.000 description 1
- 208000006379 syphilis Diseases 0.000 description 1
- 230000037317 transdermal delivery Effects 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US4045908P | 2008-03-28 | 2008-03-28 | |
| US61/040,459 | 2008-03-28 | ||
| PCT/US2009/038636 WO2009121004A2 (en) | 2008-03-28 | 2009-03-27 | Neutralizing molecules to viral antigens |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2011516423A JP2011516423A (ja) | 2011-05-26 |
| JP2011516423A5 true JP2011516423A5 (enExample) | 2013-05-23 |
Family
ID=41021445
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011502108A Pending JP2011516423A (ja) | 2008-03-28 | 2009-03-27 | ウイルス抗原に対する中和分子 |
Country Status (8)
| Country | Link |
|---|---|
| US (3) | US20100040635A1 (enExample) |
| EP (2) | EP2274334A2 (enExample) |
| JP (1) | JP2011516423A (enExample) |
| CN (1) | CN102046656A (enExample) |
| AU (1) | AU2009228058A1 (enExample) |
| CA (1) | CA2719201A1 (enExample) |
| IL (1) | IL208313A0 (enExample) |
| WO (1) | WO2009121004A2 (enExample) |
Families Citing this family (50)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2132312B1 (en) | 2007-03-27 | 2016-01-27 | Sea Lane Biotechnologies,llc. | Constructs and libraries comprising antibody surrogate light chain sequences |
| CA2787099A1 (en) | 2009-03-30 | 2010-10-14 | Anice C. Lowen | Influenza virus hemagglutinin polypeptides containing stem domains, vaccines and uses thereof |
| CN102482345A (zh) * | 2009-05-13 | 2012-05-30 | 航道生物技术有限责任公司 | 针对流感病毒的中和分子 |
| AU2010254136B2 (en) | 2009-05-26 | 2016-09-29 | Mount Sinai School Of Medicine | Monoclonal antibodies against influenza virus generated by cyclical administration and uses thereof |
| AU2010303568B2 (en) | 2009-10-09 | 2014-07-31 | New York Blood Center, Inc. | Immunopotentiator-linked oligomeric influenza immunogenic compositions |
| US9701723B2 (en) | 2010-02-18 | 2017-07-11 | Icahn School Of Medicine At Mount Sinai | Vaccines for use in the prophylaxis and treatment of influenza virus disease |
| US9573991B2 (en) * | 2010-03-08 | 2017-02-21 | Celltrion, Inc. | Human monoclonal antibodies derived from human B cells and having neutralizing activity against influenza A viruses |
| CN102939103A (zh) | 2010-03-30 | 2013-02-20 | 西奈山医学院 | 流感病毒疫苗及其应用 |
| JP6050747B2 (ja) * | 2010-06-17 | 2016-12-21 | トレリス バイオサイエンス リミテッド ライアビリティー カンパニー | インフルエンザ受動免疫化に有用な抗体 |
| US9534042B2 (en) | 2010-09-03 | 2017-01-03 | Fujita Health University | Influenza virus-neutralizing antibody and screening method therefor |
| EP2640831A1 (en) | 2010-11-17 | 2013-09-25 | Sea Lane Biotechnologies,llc. | Influenza virus neutralizing agents that mimic the binding site of an influenza neutralizing antibody |
| CN107417789A (zh) * | 2011-07-18 | 2017-12-01 | 生物医学学会 | 中和抗甲型流感病毒抗体及其用途 |
| EP2736928B1 (en) | 2011-07-28 | 2019-01-09 | i2 Pharmaceuticals, Inc. | Sur-binding proteins against erbb3 |
| US9512202B2 (en) | 2011-08-27 | 2016-12-06 | University Of Zurich | Multi-strain-reactive antibodies for therapy and diagnosis of influenza |
| KR20140068205A (ko) | 2011-09-20 | 2014-06-05 | 마운트 시나이 스쿨 오브 메디슨 | 인플루엔자 바이러스 백신 및 이의 용도 |
| CA2850720C (en) | 2011-09-30 | 2016-03-29 | Celltrion Inc. | Binding molecule having influenza a virus-neutralizing activity produced from human b cell |
| CN104302321A (zh) | 2011-12-05 | 2015-01-21 | 特瑞利斯生物科学有限责任公司 | 可用于被动流感免疫的抗体 |
| EP2793940B1 (en) | 2011-12-22 | 2018-11-14 | i2 Pharmaceuticals, Inc. | Surrogate binding proteins |
| US9969794B2 (en) | 2012-05-10 | 2018-05-15 | Visterra, Inc. | HA binding agents |
| KR20150104117A (ko) | 2012-12-18 | 2015-09-14 | 이칸 스쿨 오브 메디슨 엣 마운트 시나이 | 인플루엔자 바이러스 백신 및 그의 용도 |
| CN105209071A (zh) | 2013-03-14 | 2015-12-30 | 抗非特公司 | 用于提高疗效的基于鼻内递送中和抗体的组合物和方法 |
| WO2014159960A1 (en) | 2013-03-14 | 2014-10-02 | Icahn School Of Medicine At Mount Sinai | Antibodies against influenza virus hemagglutinin and uses thereof |
| EP2968520B1 (en) | 2013-03-14 | 2021-05-12 | MacroGenics, Inc. | Bispecific molecules that are immunoreactive with immune effector cells that express an activating receptor |
| CN104045709B (zh) * | 2013-08-02 | 2017-05-24 | 中国医学科学院病原生物学研究所 | 人源抗h7n9禽流感病毒中和性抗体a6、其制备方法及应用 |
| JPWO2015025900A1 (ja) * | 2013-08-23 | 2017-03-02 | 学校法人藤田学園 | 抗インフルエンザウイルス中和抗体 |
| KR102344390B1 (ko) | 2014-02-04 | 2021-12-28 | 콘트라펙트 코포레이션 | 수동 인플루엔자 면역화에 유용한 항체, 및 이의 사용을 위한 조성물, 조합 및 방법 |
| US10639370B2 (en) | 2014-02-04 | 2020-05-05 | Contrafect Corporation | Antibodies useful in passive influenza immunization, and compositions, combinations and methods for use thereof |
| US10717778B2 (en) | 2014-09-29 | 2020-07-21 | Duke University | Bispecific molecules comprising an HIV-1 envelope targeting arm |
| JP6499420B2 (ja) * | 2014-11-13 | 2019-04-10 | 公益財団法人ヒューマンサイエンス振興財団 | ワクチン及び感染防御キット |
| US20180008702A1 (en) | 2014-12-05 | 2018-01-11 | Celltrion Inc. | Adjuvant composition containing at least one influenza virus neutralizing and binding molecule and vaccine composition containing same |
| WO2016089181A1 (ko) * | 2014-12-05 | 2016-06-09 | (주)셀트리온 | 1 이상의 인플루엔자 바이러스 중화 결합 분자를 포함하는 애주번트 조성물 및 이를 포함하는 백신 조성물 |
| TWI702229B (zh) | 2014-12-19 | 2020-08-21 | 美商再生元醫藥公司 | 流行性感冒病毒血球凝集素之人類抗體 |
| US10736956B2 (en) | 2015-01-23 | 2020-08-11 | Icahn School Of Medicine At Mount Sinai | Influenza virus vaccination regimens |
| PH12017501216B1 (en) | 2015-02-05 | 2023-05-24 | Janssen Vaccines And Prevention B V | Binding molecules directed against influenza hemagglutinin and uses thereof |
| WO2017083627A1 (en) | 2015-11-13 | 2017-05-18 | Visterra, Inc. | Compositions and methods for treating and preventing influenza |
| EP3419663A1 (en) | 2016-02-24 | 2019-01-02 | Visterra, Inc. | Formulations of antibody molecules to influenza virus |
| WO2017218624A1 (en) | 2016-06-15 | 2017-12-21 | Icahn School Of Medicine At Mount Sinai | Influenza virus hemagglutinin proteins and uses thereof |
| BR112019016374A2 (pt) * | 2017-02-17 | 2020-04-07 | Bristol-Myers Squibb Company | anticorpos para alfa-sinucleína e usos dos mesmos |
| JOP20190200A1 (ar) | 2017-02-28 | 2019-08-27 | Univ Pennsylvania | تركيبات نافعة في معالجة ضمور العضل النخاعي |
| US10786568B2 (en) | 2017-02-28 | 2020-09-29 | The Trustees Of The University Of Pennsylvania | AAV mediated influenza vaccines |
| SI3589730T1 (sl) | 2017-02-28 | 2024-04-30 | The Trustees Of The University Of Pennsylvania | Adeno-povezan virus (AAV) clade F vektor in njihova uporaba |
| WO2018169785A2 (en) | 2017-03-13 | 2018-09-20 | The Government Of The United States Of America As Represented By The Secretary Of The Army | Therapeutic antibodies to marburg virus |
| WO2018187706A2 (en) | 2017-04-07 | 2018-10-11 | Icahn School Of Medicine At Mount Sinai | Anti-influenza b virus neuraminidase antibodies and uses thereof |
| SG11202006379UA (en) | 2018-01-26 | 2020-07-29 | Regeneron Pharma | Human antibodies to influenza hemagglutinin |
| WO2019210144A1 (en) * | 2018-04-27 | 2019-10-31 | Vanderbilt University | Broadly neutralizing antibodies against hepatitis c virus |
| EP3810634A4 (en) | 2018-06-21 | 2022-07-27 | Icahn School of Medicine at Mount Sinai | Mosaic influenza virus hemagglutinin polypeptides and uses thereof |
| CA3118073A1 (en) * | 2018-10-29 | 2020-05-07 | Immuno-Biological Laboratories Co., Ltd. | Anti-hiv antibody and method for producing same |
| CN113924147A (zh) | 2019-03-25 | 2022-01-11 | 威特拉公司 | 用于治疗和预防流感的组合物和方法 |
| EP3959216A4 (en) | 2019-04-24 | 2023-01-11 | Icahn School of Medicine at Mount Sinai | ANTI-INFLUENZA B VIRUS NEURAMINIDASE ANTIBODIES AND USES THEREOF |
| WO2023092314A1 (zh) * | 2021-11-24 | 2023-06-01 | 苏州方科生物科技有限公司 | 结合bp特异性抗原肽的人源抗体、制备方法及用途 |
Family Cites Families (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4485045A (en) | 1981-07-06 | 1984-11-27 | Research Corporation | Synthetic phosphatidyl cholines useful in forming liposomes |
| US4943529A (en) | 1982-05-19 | 1990-07-24 | Gist-Brocades Nv | Kluyveromyces as a host strain |
| ZA836080B (en) | 1982-08-23 | 1984-04-25 | Scripps Clinic Res | Broad spectrum influenza antisera |
| DD266710A3 (de) | 1983-06-06 | 1989-04-12 | Ve Forschungszentrum Biotechnologie | Verfahren zur biotechnischen Herstellung van alkalischer Phosphatase |
| US4544545A (en) | 1983-06-20 | 1985-10-01 | Trustees University Of Massachusetts | Liposomes containing modified cholesterol for organ targeting |
| AU3145184A (en) | 1983-08-16 | 1985-02-21 | Zymogenetics Inc. | High expression of foreign genes in schizosaccharomyces pombe |
| US4879231A (en) | 1984-10-30 | 1989-11-07 | Phillips Petroleum Company | Transformation of yeasts of the genus pichia |
| DD228737A1 (de) * | 1984-11-06 | 1985-10-23 | Inst F Angewandte Virologie | Verfahren zur herstellung von influenza-inaktivimpfstoffen mit geringer stammabhaengigkeit |
| GB8610600D0 (en) | 1986-04-30 | 1986-06-04 | Novo Industri As | Transformation of trichoderma |
| WO1988006630A1 (en) | 1987-03-02 | 1988-09-07 | Genex Corporation | Method for the preparation of binding molecules |
| GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
| US5175384A (en) | 1988-12-05 | 1992-12-29 | Genpharm International | Transgenic mice depleted in mature t-cells and methods for making transgenic mice |
| DE68927344T2 (de) | 1989-04-28 | 1997-02-20 | Rhein Biotech Proz & Prod Gmbh | Hefezellen der Gattung-Schwanniomyces |
| EP0402226A1 (en) | 1989-06-06 | 1990-12-12 | Institut National De La Recherche Agronomique | Transformation vectors for yeast yarrowia |
| DE3920358A1 (de) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung |
| FR2649120B1 (fr) | 1989-06-30 | 1994-01-28 | Cayla | Nouvelle souche et ses mutants de champignons filamenteux, procede de production de proteines recombinantes a l'aide de ladite souche et souches et proteines obtenues selon ce procede |
| US5013556A (en) | 1989-10-20 | 1991-05-07 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
| GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
| JPH07501451A (ja) | 1991-11-25 | 1995-02-16 | エンゾン・インコーポレイテッド | 多価抗原結合タンパク質 |
| JP3571337B2 (ja) | 1992-02-11 | 2004-09-29 | セル ジェネシス，インコーポレーテッド | 遺伝子標的現象による同型遺伝子接合 |
| US6337070B1 (en) * | 1993-04-29 | 2002-01-08 | Takara Shuzo Co., Ltd. | Polypeptides for use in generating anti-human influenza virus antibodies |
| US6214388B1 (en) | 1994-11-09 | 2001-04-10 | The Regents Of The University Of California | Immunoliposomes that optimize internalization into target cells |
| GB9522351D0 (en) * | 1995-11-01 | 1996-01-03 | Medeva Holdings Bv | Vaccine compositions |
| US6358709B1 (en) | 1995-12-07 | 2002-03-19 | Diversa Corporation | End selection in directed evolution |
| US6171820B1 (en) | 1995-12-07 | 2001-01-09 | Diversa Corporation | Saturation mutagenesis in directed evolution |
| US6361974B1 (en) | 1995-12-07 | 2002-03-26 | Diversa Corporation | Exonuclease-mediated nucleic acid reassembly in directed evolution |
| ES2462532T3 (es) * | 1999-10-18 | 2014-05-23 | Novartis Vaccines And Diagnostics, Inc. | Composiciones y métodos para estimular una respuesta inmune contra agentes infecciosos |
| EP1255561B1 (en) * | 2000-02-15 | 2006-06-28 | ID Biomedical Corporation of Quebec | Proteosome influenza vaccine |
| US20020119148A1 (en) | 2000-09-01 | 2002-08-29 | Gerritsen Mary E. | ErbB4 antagonists |
| EP1499887B1 (en) | 2002-04-17 | 2009-08-05 | Bioren, Inc. | Universal libraries for immunoglobulins |
| EP1517921B1 (en) | 2002-06-28 | 2006-06-07 | Domantis Limited | Dual specific ligands with increased serum half-life |
| ES2609102T3 (es) | 2003-06-27 | 2017-04-18 | Bioren, LLC | Mutagénesis por revisión |
| EP3479844B1 (en) * | 2005-04-15 | 2023-11-22 | MacroGenics, Inc. | Covalent diabodies and uses thereof |
| FR2896162B1 (fr) * | 2006-01-13 | 2008-02-15 | Sanofi Pasteur Sa | Emulsion huile dans eau thermoreversible |
| WO2007134327A2 (en) * | 2006-05-15 | 2007-11-22 | Sea Lane Biotechnologies, Llc. | Neutralizing antibodies to influenza viruses |
| CA2663388C (en) * | 2006-09-07 | 2017-01-17 | Crucell Holland B.V. | Human binding molecules capable of neutralizing influenza virus h5n1 and uses thereof |
| CA2675137A1 (en) | 2007-01-12 | 2008-07-24 | Sea Lane Biotechnologies, Llc. | Combinatorial libraries of conformationally constrained polypeptide sequences |
| EP2132312B1 (en) * | 2007-03-27 | 2016-01-27 | Sea Lane Biotechnologies,llc. | Constructs and libraries comprising antibody surrogate light chain sequences |
| FR2916107B1 (fr) | 2007-05-11 | 2015-11-27 | Centre Nat Etd Spatiales | Actionneur alternatif a asservissement en boucle fermee |
| WO2008153236A1 (en) | 2007-06-15 | 2008-12-18 | Protheon Co., Ltd | An attenuated influenza virus and a live vaccine comprising the same |
| MX2010006148A (es) | 2007-12-06 | 2011-02-23 | Dana Farber Cancer Inst Inc | Anti-cuerpos contra el virus de la influenza y metodos de uso de los mismos. |
| CA2787099A1 (en) * | 2009-03-30 | 2010-10-14 | Anice C. Lowen | Influenza virus hemagglutinin polypeptides containing stem domains, vaccines and uses thereof |
-
2009
- 2009-03-27 WO PCT/US2009/038636 patent/WO2009121004A2/en not_active Ceased
- 2009-03-27 US US12/413,308 patent/US20100040635A1/en not_active Abandoned
- 2009-03-27 CN CN2009801192684A patent/CN102046656A/zh active Pending
- 2009-03-27 AU AU2009228058A patent/AU2009228058A1/en not_active Abandoned
- 2009-03-27 JP JP2011502108A patent/JP2011516423A/ja active Pending
- 2009-03-27 EP EP09726334A patent/EP2274334A2/en not_active Withdrawn
- 2009-03-27 CA CA2719201A patent/CA2719201A1/en not_active Abandoned
- 2009-03-27 EP EP13177665.0A patent/EP2698380A1/en not_active Withdrawn
-
2010
- 2010-09-21 IL IL208313A patent/IL208313A0/en unknown
-
2011
- 2011-07-18 US US13/185,386 patent/US9169318B2/en active Active
-
2016
- 2016-06-08 US US15/177,232 patent/US20170136118A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2011516423A5 (enExample) | ||
| AU2022246465B2 (en) | Stabilized group 2 influenza hemagglutinin stem region trimers and uses thereof | |
| Laursen et al. | Broadly neutralizing antibodies against influenza viruses | |
| AU2009227567B2 (en) | Monoclonal antibodies capable of reacting with a plurality of influenza virus A subtypes | |
| JP2009537147A5 (enExample) | ||
| EP2652496B1 (en) | Vaccine antigens that direct immunity to conserved epitopes | |
| JP2012526839A5 (enExample) | ||
| US20170136118A1 (en) | Neutralizing molecules to viral antigens | |
| JP6450688B2 (ja) | 呼吸器合胞体ウイルスｆタンパク質エピトープ | |
| JP2010521147A5 (enExample) | ||
| US11103575B2 (en) | Immunogenic composition for MERS coronavirus infection | |
| US20120009212A1 (en) | Conjugates utilizing platform technology for stimulating immune response | |
| CN1332749A (zh) | 含有通过肽配体连接的多个免疫原性成分的hbv核心抗原颗粒 | |
| US20160145320A1 (en) | Broad-Spectrum Monoclonal Antibody Recognizing HA1 Domain of Hemagglutinin of Influenza Virus | |
| US10098943B2 (en) | Flavivirus virus like particle | |
| CN103483421A (zh) | 用于治疗hbv感染及相关疾病的多肽及抗体 | |
| Yewdell | Viva la revolucion: rethinking influenza a virus antigenic drift | |
| Estepa et al. | Pepscan mapping and fusion-related properties of the major phosphatidylserine-binding domain of the glycoprotein of viral hemorrhagic septicemia virus, a salmonid rhabdovirus | |
| De Jong et al. | Development of broadly reactive influenza vaccines by targeting the conserved regions of the hemagglutinin stem and head domains | |
| Boruah et al. | Single domain antibody multimers confer protection against rabies infection | |
| Stropkovská et al. | Broadly cross-reactive monoclonal antibodies against HA2 glycopeptide of Influenza A virus hemagglutinin of H3 subtype reduce replication of influenza A viruses of human and avian origin | |
| CN102238963A (zh) | 完全人源性流感m2特异性抗体 | |
| S Shcherbakova et al. | Artificial polyepitope HIV-1 immunogen containing mimotope of 2F5 epitope | |
| Sastre et al. | Comparison of antibodies directed against human respiratory syncytial virus antigens present in two commercial preparations of human immunoglobulins with different neutralizing activities | |
| JPWO2022045126A5 (enExample) |